Patent · US Active

Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

US11345741B2 · kind B2 · utility

3Cited by
1References
26Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 25, 2021
Grant dateMay 31, 2022
Priority date—
Expiry dateMar 25, 2041

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2469/10
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.